<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <meta name="description" content="Beers Criteria">
  <meta name="author" content="Andrew Dolby">

  <title>Beers Criteria</title>

  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/normalize/3.0.3/normalize.min.css">
  <link rel="stylesheet" href="css/style.css">
</head>

<body id="page-top">
  <header>
    <nav>
      <ul>
        <li class="brand">
          <span>Beers Criteria</span>
        </li>
      </ul>
    </nav>
  </header>

  <main>
    <section class="search-section">
      <input class="search-field" type="search" required />
      <label class="search-label">
        <span class="search-label-content">Search</span>
      </label>
    </section>

    <section class="results">
      <section class="card">
        <ul class="list-column">
          <li>
            <ul class="list-row">
              <li>Therapeutic Category: Drug(s)</li>
              <li>Digoxin</li>
            </ul>
          </li>

          <li>
            <ul class="list-row">
              <li>Rationale</li>
              <li>
                Use in atrial fibrillation: should not be used as a first-line agent
                in atrial fibrillation, because more-effective alternatives exist and
                it may be associated with increased mortality. Use in heart failure:
                questionable effects on risk of hospitalization and may be associated
                with increased mortality in older adults with heart failure; in heart
                failure, higher dosages not associated with additional benefit and may
                increase risk of toxicity. Decreased renal clearance of digoxin may
                lead to increased risk of toxic effects; further dose reduction may be
                necessary in those with Stage 4 or 5 chronic kidney disease.
              </li>
            </ul>
          </li>

          <li>
            <ul class="list-row">
              <li>Recommendation</li>
              <li>Avoid</li>
            </ul>
          </li>

          <li>
            <ul class="list-row">
              <li>Quality of Evidence</li>
              <li>
                Atrial fibrillation: moderate. Heart failure: low. Dosage >0.125 mg/d:
                moderate.
              </li>
            </ul>
          </li>

          <li>
            <ul class="list-row">
              <li>Strength of Recommendation</li>
              <li>
                Atrial fibrillation: strong. Heart failure: strong. Dosage >0.125 mg/d:
                strong.
              </li>
            </ul>
          </li>

          <li>
            <ul class="list-row">
              <li>Evidence</li>
              <li>
                2015 Criteria: Use in atrial fibrillation: Al-Khatib 2013,
                Turakhia 2014, Whitbeck 2013, Gheorghiade 2013a, Gheorghiade 2013b,
                Friberg 2010, Mulder 2014, Ambrosy 2014, National PBM Bulletin 2014.
                Use in heart failure: Freeman 2013. From previous criteria: Adams 2002,
                Ahmed 2007, Rathore 2003
              </li>
            </ul>
          </li>
        </ul>
      </section>
    </section>
  </main>

  <footer></footer>

  <script type="text/javascript" src="app.js"></script>
</body>
</html>
